Targeted therapy for advanced adrenal cancer
Part of Cancer clinical trials.
This trial tests two targeted drugs, anlotinib and benmelstobart, for people with advanced pheochromocytoma or paraganglioma that has spread or come back after treatment. These drugs may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced pheochromocytoma or paraganglioma that is not curable with surgery and has spread or returned.
- You are not able to have or choose not to have chemotherapy or radionuclide therapy.
- You have at least one tumor that can be measured on a scan.
- Your overall health is good enough for treatment (ECOG score 0-2).
- You have not been previously treated with anlotinib, certain other targeted therapies, or PD-1/PD-L1 inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called zanzalintinib for adults with a rare type of tumor called pheochromocytoma or paraganglioma that has spread or cannot be removed with surgery. The goal is to see if this drug can slow or stop the tumor from growing, and to evaluate its safety.
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
This trial tests a new type of radiation therapy for advanced neuroendocrine cancers that have not responded to standard treatments. It aims to see if this therapy can help shrink or control the cancer.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
This trial tests a new combination of drugs (PD-1 inhibitor, apatinib, and mitotane) for people with advanced adrenal cortical carcinoma that cannot be removed by surgery. The goal is to see if this combination is safe and effective for those who have not yet received standard first-line treatment.
This trial studies how adrenal hormone tumor diseases should be diagnosed, treated, and followed over time. It may help people get more precise care and better prediction of outcomes, but it has specific health and medication requirements.
Hear when a new Pheochromocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.